Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MYC | P01106 | 2/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | ELANE | P08246 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | PRKDC | P78527 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733038 | 0.83 | ALDH1A1 (0.62) | KDM4EALDH1A1POLBHPGDMEN1 | |
| SCHEMBL27107055 | 0.83 | ADRB1 (0.63) | KDM4EALDH1A1HSD17B10MYCKLKB1 | |
| SCHEMBL14080465 | 0.83 | ADRB1 (0.63) | KDM4EALDH1A1HSD17B10MYCTSHR | |
| SCHEMBL12306058 | 0.82 | MYC (0.57) | KDM4EALDH1A1POLBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL15929282 | 0.81 | ADRB1 (0.61) | KDM4EALDH1A1HSD17B10MYCTSHR | |
| SCHEMBL5058525 | 0.81 | PRKDC (0.75) | KDM4EALDH1A1POLBHPGDMEN1 | |
| SCHEMBL18553757 | 0.81 | CCNC (0.53) | KDM4EALDH1A1POLBHPGDMEN1 | |
| SCHEMBL22551217 | 0.80 | KDM4E (0.49) | KDM4EALDH1A1HSD17B10TSHRUSP2 | |
| SCHEMBL20231055 | 0.80 | KDM4E (0.49) | KDM4EALDH1A1HSD17B10PRKDCTSHR | |
| SCHEMBL13182828 | 0.79 | ADRB1 (0.56) | KDM4EALDH1A1ADRB1HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LTD (IE) | 2018-03-08 | — | — | US | claimed |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | claimed |
| EP-2844242-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | Nogra Pharma Limited (IE) | 2015-03-11 | — | — | EP | claimed |
| CN-104284655-A | Methods of treating lactose intolerance | NOGRA PHARMA LTD | 2015-01-14 | — | — | CN | claimed |
| WO-2013156413-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2013-10-24 | — | — | WO | claimed |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | NOGRA PHARMA LIMITED (IE) | 2011-06-23 | — | — | US | claimed |
| EP-2131829-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | Giuliani International Limited (IE) | 2009-12-16 | — | — | EP | claimed |
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2009-05-07 | — | — | US | claimed |
| WO-2008104557-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | GIULIANI INTERNATIONAL LIMITED (IE) | 2008-09-04 | — | — | WO | claimed |
| EP-1910275-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | Giuliani International Limited (IE) | 2008-04-16 | — | — | EP | claimed |
| WO-2007010514-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-01-25 | — | — | WO | claimed |
| US-12291494-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2025-05-06 | — | — | US | disclosed |
| US-20240279157-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2024-08-22 | — | — | US | disclosed |
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | disclosed |
| CN-116602950-A | Methods of treating fibrosis | 诺格拉制药有限公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-2131829-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | Giuliani International Limited (IE) | 2009-12-16 | — | — | EP | disclosed |
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2009-05-07 | — | — | US | disclosed |
| WO-2008104557-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | GIULIANI INTERNATIONAL LIMITED (IE) | 2008-09-04 | — | — | WO | disclosed |
| EP-1910275-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | Giuliani International Limited (IE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010514-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | EGFR, ERBB3, FGFR3 | KDM4E 4603/4885ALDH1A1 2287/4885POLB 2759/4885 |
| US-11753365-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | KDM4E 2967/4885ALDH1A1 664/4885POLB 2470/4885 |
| US-20240279157-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | KDM4E 2967/4885ALDH1A1 664/4885POLB 2470/4885 |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | KDM4E 4341/4885ALDH1A1 530/4885POLB 4205/4885 |
| US-12291494-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | KDM4E 2967/4885ALDH1A1 664/4885POLB 2470/4885 |
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | KDM4E 4341/4885ALDH1A1 530/4885POLB 4205/4885 |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | PPARG, FABP2, PPARD | KDM4E 4571/4885ALDH1A1 983/4885POLB 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.